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ANTICANCER ACTION OF MIBEFRADIL

by

AHMED GHAREEB

Under the Direction of Dr. Ritu Aneja

ABSTRACT
Cancer is the modern, most persistent serial killer. Cancer cells intelligently recruit and
utilize all the biological functions to support their survival, proliferation, and invasion, which
require altering and reprogramming a lot of the normal signals and pathways. Calcium (Ca2+) is a
fundamental secondary messenger involved in most of the regular cellular functions, not only the
survival processes but also, the apoptotic death. Cancer cells exhibit unique expression levels of
T-type Ca2+ channels (TTCC) that vary according to the tumor type, stage, and the channel
isoform. The aberrant expression of the TTCC family (Cav3.1, Cav3.2, and Cav3.3) genes in
cancer cells significantly contribute in the remodeled Ca2+ signaling that mediates many cancer

cell functions including mitochondrial energy production, proliferation, angiogenesis, metastasis,
and sensitivity to cell death. Accordingly, the TTCC blockers were proposed for their anti-cancer
effect. Mibefradil (MBF) (Posicor®) is a TTCC blocker initially introduced into the
pharmaceutical market in 1997 as an FDA-approved antihypertensive drug but voluntarily
withdrawn due to drug-drug interactions. 10 years later, MBF was qualified for drug orphan
designation by the FDA for the treatment of pancreatic, ovary, and brain cancers. Herein, we
investigate the anti-cancer effect of MBF on different cell lines by determining its IC50 and
indicate MBF-induced endoplasmic reticulum Ca2+ release as a key for the anticancer effect of
MBF. Moreover, we identify the effect of MBF on important cytoplasmic organelles such as
mitochondria and lipid droplets (LDs). Further, we demonstrate that MBF reduces the number of
the lipid droplets and affects the cellular lipid storage by inducing lipolysis in cancer cells.

INDEX WORDS: Cancer cell, T-type Ca2+ channels, Mibefradil, Thapsigargin, Lipid droplets,
Lipolysis.
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1- INTRODUCTION

Calcium (Ca2+) is a ubiquitous and highly dynamic signaling molecule that controls a
wide range of cellular functions. The momentarily intracellular Ca2+ concentration differs
according to the ‘on’ reactions responsible for Ca2+ influx to the cytoplasm and the ‘off’
reactions causing Ca2+ removal. During the ‘on' reactions, a small amount of Ca2+ binds the
effectors, which stimulates several Ca2+ dependent processes (Barrige et al., 2003; Monteith et
al., 2012).
The Ca2+ signaling is highly versatile and functionally compartmentalized according to
the spatial and temporal parameters. The on/off Ca2+ dependent reactions are highly involved in
most of the cellular survival mechanisms and programmed cell death. Therefore, Ca2+
homeostasis is a fundamental requirement for the cell survival that is achieved by the continuous
flow of Ca2+ fluxes and correspondingly balanced and matched during the off and on reactions
(Barrige et al., 2003; Monteith et al., 2012).
T-type Ca2+ channels (TTCC) are low-voltage-activated (LVA) Ca2+ channels that start
opening when the cell is depolarized between -60 and -40 mV. Therefore, TTCC need more
negative potential than other voltage-gated Ca2+ channels. They are inactivated rapidly after
opening but close much slower than other voltage-gated Ca2+ channels. For this reason, they are
termed slowly deactivating T-type channels (Ertel and Ertel, 1997).
Tumorigenesis is associated with several mutations that exclusively establish the cancerspecific characters, including self-dependent growth signals, and apoptosis evasion. Thus, some
cancer cells exhibit deregulated or remodeled Ca2+ signaling pathways that are essential for
sustaining the phenotypic transformation (Roderick and Cook, 2008).
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Further, the altered Ca2+ signaling system (Ca2+ toolkit) contributes to cancer progression
by mediating the proliferation, invasiveness, and acquisition of chemotherapeutic resistance
(Bergner et al., 2009; Cardenas et al., 2018). Consequently, cancer cells exhibit a variant
expression of TTCC compared to normal cells, which also differs according to the tumor stage,
type and channel isoform (Monteith et al., 2012; Sallán et al., 2018)
As cancer cells undergo uncontrolled proliferation that recruits highly functional cellular
mechanisms, the Ca2+ influx through the TTCC is essential for performing those functions
associated with cancer (Büsselberg and Florea, 2017; Monteith et al., 2017). Moreover, the
relationship of TTCC expression and Ca2+ influx with cancer cell proliferation and apoptosis has
been presented in different tumors such as glioma (Valerie et al., 2013; Zhang et al., 2012),
hepatoma (Li et al., 2009), ovarian (Heo et al., 2008; Li et al., 2011), melanoma (Das et al.,
2012), breast (Taylor et al., 2008), leukemia (Toyota et al., 1999), colon (Dziegielewska et al.,
2013), and esophageal cancers (Lu et al., 2008).
Cav3.2 overexpression is associated with proliferation and hypoxia markers. In addition,
the Cav3.1 overexpression was associated with BRAFV600E mutation and autophagic activity in
melanoma cells. Moreover, Cav3.2 transcriptional factors and proteins are excessively expressed
in some glioblastoma multiforme tumors; similar findings for the Cav3.1 expression were
reported in Glioblastoma Stem Cells (Maiques Carlos et al., 2018).
Accordingly, the TTCC was suggested as a target for investigating anticancer effects,
either by pharmacological inhibition or Cav3.2 gene silencing (Monteith et al., 2012). The
pharmacological inhibition of TTCC by Mibefradil (MBF) decreased cells proliferation through
p53-dependent upregulation of CDK inhibitor p21, arresting the G1–S progress in human
esophageal carcinoma (Lu et al., 2008). Additionally, MBF-induced activation of the p38
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mitogen-activated protein kinase (p38–MAPK) pathway mediated p53 accumulation, causing
cell-cycle halt and programmed death in colon cancer cells (Dziegielewska et al., 2013).
In addition, pharmacological blockage of TTCCs or Cav3.2 gene interference inhibited
the expression of high voltage-activated (HVA) Ca2+ channels and the cAMP-induced
neuritogenesis in neuroblastoma-glioma cells (NG108-15), which indicates the dual role of
TTCC at the initial stages of neuronal differentiation, in controlling the morphological changes
and membrane excitability (Chemin et al., 2002). Additionally, MBF and ascorbic acid (Cav3.2
inhibitor) diminished the H2S-induced differentiation of NG108-15 cells that involves Src kinase
phosphorylation (Tarui et al., 2010).
Moreover, MBF in-vitro treatment of Glioblastoma stem cells suppresses multiple
oncogenic pathways through downregulation of hypoxia-induced and anti-stress transcriptional
factors HIF1a and HIF2, inhibits vascular endothelial growth factor (VEGF) expression and
survivin (apoptosis inhibitor protein). Also, MBF triggered the apoptotic cell death through the
activation of caspase-9, BAX, PARP, Rb, and p27 in Glioblastoma stem cells (Zhang et al.,
2017). Additionally, MBF was shown to improve ovarian cancer cells sensitivity to carboplatin
(platinum-based anticancer drug) both in-vitro and in-vivo, by reducing Protein Kinase B
phosphorylation and down-regulation of survivin expression that abolishes the platinum
resistance in ovarian cancer (Dziegielewska et al., 2016).
In-vitro administration of MBF and its structural analog (NNC-55-0396) to leukemia cell
lines suppresses cell proliferation and growth by down-regulating the ERK signaling pathway
through intracellular Ca2+ regulation that modulates the activation of p44/42 MAP kinase; also,
NNC-55-0396 disturbs the intracellular Ca2+ homeostasis, causing Ca2+ efflux from the ER. The
released Ca2+ affects the mitochondria through mitochondria-associated endoplasmic reticulum
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(ER) membranes, resulting in mitochondrial depolarization, swelling, and uncoupling (Huang et
al., 2015).
Taken together, inhibition of TTCC disrupts the intracellular Ca2+ homeostasis, resulting
in ER and mitochondrial stress; consequently cells exhibit mitochondrial loss of function and
apoptotic cell death (Huang et al., 2015). Further, in-vivo studies using an immune-deficient
xenograft mouse model showed that the application of NNC-55-0396 (MBF analog) suppressed
ovarian cancer growth (Huang et al., 2004). Moreover, the oral administration of MBF improved
the efficacy of subsequent administration of temozolomide (alkylating antineoplastic agent used
for brain cancer treatment) in glioblastoma multiforme tumor burden mice (Stupp et al., 2002).
Interestingly, cancer cell exhibits abnormal lipid metabolism associated with increased
lipogenesis. The high rate of lipid production in cancer cells is essential for several biological
functions, such as energy storage, cellular signaling, and production of phospholipids blocks
required for proliferation. The cancer microenvironment is characterized by improper oxygen
supply (hypoxia) and nutrient scarcity. Consequently, cancer cells establish the Warburg effect
by exhibiting excessive glucose uptake and glycolysis rate, associated with an increase in fatty
acid synthesis, fatty acid uptake, and lipid content to be stored in LDs. Several studies have
linked the aggressiveness of tumors with the abundance of LDs. Usually, cancer cells utilize the
lipid stored in LDs upon need by recruiting the autophagy pathway to include the LD in
autophagosomes that fuse with a lysosome to form an autolysosome. Hence, the cancer cell
shows a modified lipolysis mechanism correlated with lipophagy. Moreover, a relation between
ER-stress and lipophagy in cancer cells has been reported (Maan et al., 2018).
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Despite the early diagnosis and advanced medical interventions, the number of cancer
patients is increasing dramatically. In addition to the rate of resistance, recurrence, and collapse
continuously grow. Further, cancer patients are vulnerable to numerous side effects due to
radiotherapy and chemotherapy (Carr et al., 2014; Seegenschmiedt, 2004). Therefore, there is an
urgent need for a comprehensive research to understand the molecular and physiological changes
of cancer cells to introduce a highly specific anticancer therapy with minimal side effects.
Herein, this study shows the efficacy of MBF in different cancer cell lines by evaluating
its IC50.We also identified the MBF-induced ER Ca2+ release as an essential event for the
observed effects of MBF. Moreover, our data indicate a unique effect of MBF on mitochondrial
membrane potential and cytosolic lipid droplets in cancer cells.
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2- CHAPTER 1
THE ANTICANCER ACTION OF MIBEFRADIL
ON DIFFERENT CANCER CELL LINES

2.1

Introduction:

The TTCC blockers were proposed to have anticancer effects due to the identified unique
expression of TTCC in different cancer cells and their essential role in Ca2+ signaling that
controls most of cancer cells functions (Monteith et al., 2012; Sallán et al., 2018).
Administration of MBF at a dose of 10 µM into human non-small-cell lung cancer
(A549) cells showed 66% G1-phase arrest after 24 and 48 h of treatment. (Byun et al., 2016).
Blocking TTCC with MBF inhibited the growth of the leukemia cell lines, MOLT-4 (T
lymphoblast) and Jurkat (immortalized T lymphocyte) cells, about 20% to 40% after 48 h
treatment in doses between 5 to 10 µM respectively. The MBF significantly increased the
number of cells arrested in the sub-G1 phase, which is an indicator of apoptosis in both cell lines.
MBF modulated the expression of p44/42 MAP kinase in MOLT-4 cells and decreased the
phosphorylation of pERK1/2 in a dose-dependent pattern, which suggests that the effect of MBF
on cytosolic Ca2+ concentration [Ca2+]i might modulate the phosphorylation activation of p44/42
MAP kinase that accordingly might contribute in inhibiting the cells growth (Huang et al., 2015).
In Glioblastoma multiforme (GBM) tumor cells, MBF inhibited the cell survival with
IC50 ~ 5 µM and induced apoptosis. Also, administration of MBF reduced the phosphorylation of
the mTORC2 subunit and phospho-Akt that are important proteins for tumor sustainability.
Further, MBF-induced GBM cells apoptosis by increasing caspase-3/7 activity, PARP and DNAPK cleavage; those apoptosis associated events have not been shown with the administration of
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L-type Ca2+ channels (LTCC) blockers. Also, MBF elevated the level of caspase-8 cleavage and
Bid degradation that contributes to the apoptosis pathway (Valerie et al., 2013).
In-vivo, oral administration of MBF alone at a dose of 45 mg/kg, four times daily,
potentially delayed the Glioblastoma multiforme (GBM) tumor growth in a xenograft mouse
model. Further, combining the previously described dose of MBF with temozolomide at a dose
of 10 mg/kg/day through intraperitoneal injection, resulted in 100% tumor inhibition after 50
days of treatment (Keir et al., 2013).
Administration of MBF to A2780, A2780Cis, and IGROV-1 cells (cisplatin-resistant
ovarian cancer cell lines) showed dose-dependent growth inhibition with IC50 about 7, 8, 10 µM
respectively. Further, the MBF treated cells exhibited cell cycle arrest in G1 and G2 phases and a
reduced number of cells enter S phase, which accompanied with a dose-dependent reduction in
the expression of p27, cyclin D1, and Rb, and decreased phosphorylation of Rb as well
(Dziegielewska et al., 2016; Jang et al., 2013; Li et al., 2011).
Also, the sub-G1 population of ovarian cells was increased after MBF treatment, which
indicates cell-cycle arrest. Administration of MBF at a dose of 10 µM for 24 h increased the
expression of prominent apoptosis markers: caspase 9, caspase 7, and cleaved PARP, and
decreased the expression of the anti-apoptotic factor “survivin”. Further, coadministration of
MBF with carboplatin overcame the cisplatin resistance of ovarian cancer cells (A2780Cis) and
increased the cells sensitivity to carboplatin both in-vitro and in-vivo. The in-vivo study was
performed on nude mice that were intraperitoneally injected with cisplatin-resistant ovarian
cancer cells (Dziegielewska et al., 2016).
MBF treatment induced a dose-dependent inhibition in the viability of Glioma-initiating
cells (GIC) for doses less than 10 mM. Also, MBF was indicated to alter the plasma membrane
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potential of GIC, thus affecting glucose transport and leading to cell starvation. Also, the effect
of MBF on the intracellular Ca2+ homeostasis induced ER stress and triggered the unfolded
protein response of the ER that resulted in cell death via apoptosis (Niklasson et al., 2017).
Furthermore, treating the Glioblastoma stem-like cells (GSC) with 5 μM of MBF for 5 days
significantly decreased cell proliferation and induced cell death (Zhang et al., 2017).
The continuous growth of the tumor mass increases the distance between the tumor cells
and the blood vessels. Consequently, cancer cells, especially those at the center of the tumor
mass, suffer from low oxygen tension (hypoxia). Tumor cells overcome the hypoxia associated
with the tumor mass by overexpressing HIF1α and HIF2α, which act as anti-stressors and
antiapoptotic factor (Keith et al., 2012).
Moreover, hypoxic GSCs are shown to overexpress the Cav3.2 coincidently with HIF1α
and HIF2α overexpression. Treating GSCs with MBF at a dose of 5 μM decreased the HIF1α
and HIF2α expression that allows the cells to undergo stress-induced apoptosis. Also, MBF in
the same dose reduced the effect of the mTOR protein that associated with the tumor initiation
and development, also, resulted in the overexpression of the proapoptotic proteins Bax and p27.
Additionally, oral treatment of GSC tumor burden mice (tumor cells were injected in corpus
striatum) with MBF at a dose of 24 mg/kg every 6 hours significantly inhibited tumor growth,
which was measured using magnetic resonance imaging (MRI) (Zhang et al., 2017).
In digestive system cancers, MBF was shown to decrease the proliferation of esophageal
carcinoma cells by overexpression of cyclin-dependent kinase inhibitor (p21Cip1/Waf1) (Lu et
al., 2008). Moreover, MBF administration into colon cancer cells (HCT-116) induced apoptosis
due to the overexpression of the tumor suppressor protein (p53), p53 upregulated modulator of
apoptosis (PUMA), and p21Cip1/Waf1(Dziegielewska et al., 2013).
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The MTT (3-[4,5-dimethyl-2-thiazolyl]-2, 5-diphenyl-2H-tetrazolium bromide) assay is
commonly used to measure cellular viability, toxicity, and proliferation (Dziegielewska et al.,
2013; van Meerloo et al., 2011). MTT is water-soluble, can be dissolved in the growth medium,
and is easily taken up by cells via endocytosis (Liu et al., 1997). The MTT dye is reduced by
cellular dehydrogenases and reducing agents, especially mitochondrial succinate dehydrogenase,
into an insoluble formazan dye that can be dissolved using organic solvents such as DMSO. The
reducing power of the cell mainly depends on reducing of nicotinamide adenine dinucleotide
coenzyme (NAD), as well as many other intracellular reducing compounds, such as
dihydrolipoic acid, ascorbic acid, cysteine, glutathione, and tocopherols. Therefore, the MTT
assay is considered as a comprehensive indicator of mitochondrial activity and cellular viability
accordingly. Usually, the MTT assay can be used to measure the change in the cellular viability
after a particular treatment. The amount of produced formazan is directly proportional to the
number and activity of the cells that can be estimated by measuring the optical density of formed
formazan crystals after being dissolved in DMSO. The accuracy of the MTT assay comes from
comparing the amount of the formazan produced from treated cells against untreated cells under
the same condition (Van den Berg, 2015).

2.2
2.2.1

Materials and Methods:
MTT Assay for Different Cancer Cell Lines:

MTT MTT (3-[4,5-Dimethylthiazol-2-Yl]-2,5-Diphenyltetrazolium Bromide) assay was
performed for detecting the effect of MBF on the viability of various cancer cell lines and for
estimating the IC50 (half maximal inhibitory concentration) of the MBF for different cancer cell
lines. The cells were seeded in 96 well plates at a density ≃ 5000 cells per well in 100 µL of
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suitable medium. Three 96 well plates were inoculated for each cell line (triplicate). The plates
were incubated for 24 hours (h) in standard conditions (5 % CO2 at 37 oC), which is required for
cells to attach. The medium was exchanged with medium containing MBF in the tested wells
(Number of repeats [N] = 6 wells, columns 4-12, rows A-F). Doxorubicin hydrochloride (an
FDA approved anticancer drug, Cayman Chemical, MI, USA) was used as the positive control
(N = 6 wells, columns 4-12, rows G, H), N = 2. All drugs were prepared as dimethyl sulfoxide
(DMSO) stock solutions. The negative control wells (N = 24 wells, columns 1-3, rows A-H)
were treated with DMSO. The DMSO final concentration was 1% in all wells. The columns of
MBF and doxorubicin were treated in two-fold serial dilution (50, 25, 12.5, 6.3, 3.1, 1.6, 0.8, 0.4
µM) (Figure 1). After 48 h incubation in standard conditions, the medium was removed, and the
cells were washed with 1x DPBS (Corning®). For each well, 100 µL of (0.5 mg/mL) MTT dye
(Thiazolyl Blue Tetrazolium Bromide, Sigma-Aldrich®) was added in the appropriate medium.
After 4 h incubation in standard condition, the medium containing the MTT dye was removed
and 100 µL DMSO was added for each well, and the plates were incubated in the dark for 30
minutes in order to dissolve the formazan crystals. The optical densities (ODs) of the contents of
the wells were measured using a microplate reader (MD SPECTRAmax Plate Reader) at
wavelength 570 nm. For each MBF and positive control conc, the mean of the percentage
Average OD of the treated wells

inhibition was calculated using the following equation: Average OD of the control wells (N=24) × 100.
Also, the logarithm of the treatment concentration (Log) and the standard deviation (SD)
were calculated using Microsoft Excel. To estimate the IC50, the % inhibition versus Log
concentration was analyzed using the GraphPad Prism 6 (GraphPad Software, CA, USA) for
nonlinear regression analysis.
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2.2.2

Statistical Analysis:

GraphPad Prism 6 software was used for data plotting, graphing, and statistical analysis.
The results were calculated by Microsoft Excel to obtain the log concentration of the drugs, the
percentage viability of the cells in each well and standard deviation (SD). The curves were fitted
using GraphPad nonlinear regression by blotting the log concentration of the drug versus the
average viability, SD, and N (number of repeats). The data were analyzed by GraphPad as
inhibitor versus response (variable slope) to conclude the IC50.
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Control “DMSO”

MBF

MBF
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MBF

MBF

MBF
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12.5 µM
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Figure 1 The treatment design of the MTT assay.

Figure 1: MTT assay for in-vitro detection of the anticancer effect of MBF on various
cancer cell lines in 96 well plates. The effect of MBF was estimated against negative control
cells treated with DMSO in equal conc. Also, the MBF IC50 was compared with the positive
control rows that were treated with doxorubicin.
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2.3
2.3.1

Results:
The Effect of MBF on the Viability of Various Cancer Cell Lines:

In-vitro administration of MBF to various cancer cell lines in both 24 and 48 h assays
reduced the cells’ viability and showed markedly low IC50 values that are relatively close to the
IC50 values of the positive control drug doxorubicin hydrochloride. The MTT assay was used for
determining the cells’ viability after treatment with MBF and doxorubicin in different doses (50,
25, 12.5, 6.3, 3.1, 1.6, 0.8, 0.4 µM). Treating the triple negative breast cancer cells (TNBC)
(MDA-MB-231, MDA-MB-468, and HCC-1806), Pancreatic cancer cells (CFPAC-1, Panc-1,
and Panc-89), and Prostate cancer cells (DU-145) with MBF significantly affected the cells’
viability in a dose dependent manner. Cell survival was decreased by increasing the MBF
concentration over 1 μM (Figure 2, A-G). The non-linear regression analysis of the 48-h MTT
assay showed IC50 values of MBF ranging from 4 - 11 μM (Table 1, A). The 24-h treatment of
TNBC (MDA-MB-231 Luciferase) and prostate cancer cells (PC-3 Luciferase) showed higher
IC50 values, 23 and 24 μM respectively (Figure 2, H, I) (Table 1, B). In both assays, treating the
cells with MBF concentrations smaller than 1 μM did not have an effect on cell viability after 24
h and 48 h of treatment.
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Figure 2 Nonlinear regression analysis of MTT results using GraphPad Prism 6.

Figure 2: The non-linear regression analysis of the MTT assay results using
GraphPad Prism 6 indicates a sigmoid relation between the log MBF concentration and the
cells’ viability. (A-G) Treating various cancer cells with MBF for 48 h resulted in dosedependent inhibition. MBF concentration higher than 20 μM caused more than 80%
inhibition in viability, while 1 μM and less did not impact the viability. (H-I) The 24-h assay
also showed sigmoid relation, but the effective concentration was almost double that of the
48-hour assay.
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Table 1: The MBF IC50 doses for different cancer cell lines were calculated using the
GraphPad nonlinear regression analysis of the sigmoid relation between the Log of MBF
concentration and the % viability (A) The 48-h MTT assay of different cancer cell lines indicated
the MBF IC50 from 4 to 11 μM, while doxorubicin, which is effective only on breast and prostate
cancer cells, showed an IC50 was between 3 – 1 μM. (B) The 24-h MTT assay of two cell lines
showed higher IC50 than 48-h assay.

Table 1 The MBF IC50 doses for different cancer cell lines.
(A)

Cell Line

MBF IC50

Doxorubicin IC50

MDA-MB-468 (TNBC cells*)

4 µM

2 µM

MDA-MB-231 (TNBC cells)

9 µM

3 µM

HCC-1806 (TNBC cells)

8 µM

1 µM

DU-145 (Prostate cancer cells)

7 µM

1 µM

CFPAC-1 (Pancreatic adenocarcinoma cells)

6 µM

-

PANC-1 (Pancreatic cancer cells)

11 µM

-

PANC-89 (Pancreatic cancer cells)

5 µM

-

(B)

Cell Line

MBF IC50

PC-3 Luc (Prostate cancer cells)

≃ 23 µM

MDA-MB-231 Luc (TNBC cells)

≃ 24 µM
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2.4

Discussion:

Recently, there were many studies that investigated the anticancer effect of MBF on
specific cell lines, especially on glioma cells. Therefore, identifying the anticancer effect of MBF
on variant cancer cell lines and detecting its IC50 for those different cells confirms the inhibitory
action of MBF on cancer cells and can suggest that MBF targets a common pathway in cancer
cells. Since TNBC and pancreatic cancer cells cause serious and life-threatening illnesses, this
study paid more attention to investigating the effect of MBF on both cancer cell lines spatially
HCC-1806 and CFPAC-1 cells respectively.
Initially, the MTT assay was performed for identifying the effect of MBF on the activity
and viability of different cancer cells. Because the MTT dye is reduced by the mitochondrial
dehydrogenases (Van den Berg, 2015), the MTT assay measures the mitochondrial enzymatic
capacity as is a useful indicator of cell viability. Without intact mitochondria, cells cannot
survive or divide, and mostly undergo apoptosis. While the amount of produced formazan is
dependent on overall mitochondrial activity, it is reflective of mitochondrial function, but also on
the number of cells.
Administration of MBF to different cell lines resulted in significant inhibition of cell
survival in comparison to the DMSO-treated control cells (Figure 3). The MBF IC50 values were
between 4-11 µM. MBF in doses equal to or less than 1 µM had no effect on cell viability in
either of the cell lines. The cells treated with doxorubicin as a positive control exhibited IC50
values between 1-3 µM. Thus, MBF inhibited the cancer cells with an IC50 relatively similar to
that of doxorubicin, an FDA approved anticancer chemotherapy drug (Table 1).
Because the MTT assay was carried out over 48 h, the cells had time to perform one or
two cycles of cell division. Therefore, while the MTT results are an indicator of mitochondrial
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function, changes in formazan concentration can result from mitochondrial dysfunction leading
to cell death and apoptosis, effects on proliferation, or both, as fewer cells consequently will
produce less formazan dye. The overall results indicate that MBF has an inhibitory effect on cell
survival and/or proliferation. Therefore, the effect of MBF on cell death either apoptosis or
necrosis can be determined by AnnexinV/PI apoptosis assay.
The inhibitory effect of MBF on TTCC and other ion channels was at the heart of
multiple studies over the last 20 years (Sallán et al., 2018; Strobeck et al., 1999). The reported
IC50 dose of MBF for inhibition of? TTCC was 0.14 – 0.27 µM (Perez-Reyes, 2003). Given our
findings that the IC50 dose of MBF for different cancer cells was more than 40 times the required
concentration for blocking the TTCC, and at least 6 times the concentration required for
inhibiting voltage-gated Na+ channels and volume-activated Cl- channels, we conclude that MBF
causes cancer cell death by a mechanism other that the proposed inhibition of TTCC.

2.5

Conclusion:

MBF exhibited a potent inhibitory effect on the viability of different cancer cells. MBF
inhibited cancer cells in a dose-dependent manner. It had no effect at concentrations less than 1
µM and showed complete inhibition at concentrations higher than 25 µM. The IC50 values of
MBF for different cancer cell lines ranged from 4-11 µM, which is more than 40 times the IC50
dose for blocking TTCC.
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3- CHAPTER 2
REGULATION OF INTRACELLULAR CALCIUM SIGNALING BY MIBEFRADIL

3.1

Introduction:

Calcium ions (Ca2+) play a fundamental role in the cellular biological functions. Usually,
Ca2+ signaling takes place upon increasing the intracellular Ca2+ concentration in cells (Berridge,
1997). The temporal and spatial change of [Ca2+]i act as “on” and “off” signals allowing the cell
to depend on Ca2+ as a secondary messenger.
The

extracellular

Ca2+

concentration

is

about

10,000-fold higher

than

the

intracellular concentration. Therefore, the plasma membrane contains various types of Ca2+
channels that regulate Ca2+ influx into the cell so that Ca2+ can perform specific signaling
functions. For switching the Ca2+ signal into “off” mode, the cell quickly gets rid of the excess
cytosolic Ca2+ by recruiting Ca2+ATPases in the plasma and ER membranes, and exchangers in
the plasma membrane that exploit the concentration gradient of some other ions such as Na+. The
ER is the principal store of Ca2+ inside the cell and it maintains about 103 to ~104 times the
[Ca2+]i (Samtleben et al., 2013).
The Ca2+ is released from the ER upon specific signals, such as inositol
trisphosphate (IP3),

and

restored

by

specific

Ca2+ATPases

called

SERCA

(Sarcoplasmic/endoplasmic reticulum Ca2+ATPase) that can be blocked by Thapsigargin (Thap)
(Lytton et al., 1991).
Also, mitochondria have an important role in regulating the [Ca2+]i by operating a Ca2+
uniporter that has low affinity but a high capacity for taking the cytosolic Ca2+ into the
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mitochondria. Some of the cytosolic Ca2+ removal mechanisms can contribute to a cytoplasmic
increase in Ca2+ concentration (e.g., reverse-mode Na+/ Ca2+ exchange and Ca2+ATPases). In
addition, mitochondria can elevate [Ca2+]i by increasing its membrane permeability and releasing
Ca2+ into the cytosol (Berridge et al., 2000; Ichas et al., 1997; Lipp and Niggli, 1994; Montero et
al., 2000).
Many important cellular functions are mediated by Ca2+ signaling, including cell
contraction, crosstalk, membrane excitability, secretion, metabolism, vesicle trafficking,
proliferation, and cancer cell proliferation and metastasis, in addition to roles in mitochondria
that involve ATP production and apoptosis (Berridge et al., 2000). In cancer cells, altered Ca2+
signaling and increased Ca2+ influx were found to contribute to tumor progression by promoting
proliferation, enhancing invasiveness, and granting chemotherapeutic resistance (Büsselberg and
Florea, 2017; Monteith et al., 2017).
In the carcinogenesis process, cells undergo multiple mutations that trigger an abnormal
and uncontrolled division, which requires an increase in metabolic demand, resistance to cellular
stress and suppression of apoptosis. Most of the biological functions related to cancer formation
and progress depend on Ca2+ signaling. Therefore, cancer cell shows more frequent Ca2+
signaling and overexpression of Ca2+ channels including TTCC. Also, cancer cells depend on a
highly active ER and conduct de novo lipogenesis at a high rate (Monteith et al., 2007; Roderick
and Cook, 2008; Sallán et al., 2018).
The benzimidazolyl-substituted tetraline derivative MBF is a Ca2+ channel blocker that
inhibits L-type Ca2+ channels in the cardiovascular system (Clozel et al., 1997), while in the
arterial and vascular myocytes, it preferentially blocks T-type Ca2+ channels (Bezprozvanny and
Tsien, 1995; Clozel et al., 1997; Vortherms et al., 2011). MBF was found to inhibit TTCC and
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LTCC, with higher affinity of about 10 to 15-fold for TTCC over LTCC. The reported IC50 for
TTCC and LTCC channels was ~1 and ~50 nM, respectively (Martin et al., 2000).
Interestingly, MBF was also shown to block voltage-gated Na+ channels with an IC50
dose ~ 1 µM (Eller et al., 2000; McNulty and Hanck, 2004). In addition, MBF was found to
block N-type calcium channels (high voltage activated channels) at an IC50 dose of 7.51 µM
(Vortherms et al., 2011). Another study identified that the inhibitory effect of MBF on voltagegated Na+ channels depended on the state of the channel (state-dependent), meaning that MBF
had a preferential affinity to certain channel conditions over others; for example, the blocking
effect of MBF on Nav1.5 was greater when the cell was held at -100 mV than at -130 mV
(McNulty and Hanck, 2004).
Moreover, MBF showed an inhibitory effect on volume-activated Cl- channels with a
Ki=5.4±0.22 µM (Nilius et al., 1997). The highest reported MBF IC50 dose that blocks cloned
TTCC was 0.14 – 0.27 µM; this experiment was conducted in ~ 2 mM Ca2+ (Perez-Reyes, 2003).
Mitochondria-associated ER membranes are the normal connection between the
mitochondria and ER and are rich in enzymes, channels including Ca2+ channels, and proteins
including those with oncogenic/oncosuppressive functions. Cancer cells exhibit an alteration in
the Mitochondria-associated ER membranes function and activity such as increasing the ERMitochondria interface in breast cancer cells through Sig1R (stress-activated chaperone sigma-1
receptor) overexpression and decreasing the Ca2+ current through the ER-Mitochondria interface
for reducing the apoptosis (Morciano et al., 2018).
Treating Jurkat cells (immortalized human T cells) with topoisomerase inhibitor
“camptothecin” caused mitochondria membrane hyperpolarization, resulting in releasing of
cytochrome c. Releasing of cytochrome c from the inner membrane of mitochondrion to the
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cytoplasm activated caspases that are protease enzymes triggering programmed cell death
“apoptosis”.(Sanchez-Alcazar et al., 2000).
Using the fluorescent Ca2+ indicator, Fura-2 AM (Fura-2-acetoxymethyl ester), is a very
common and efficient means to detect and quantify changes in the cytosolic [Ca2+]i. After
loading cells with Fura-2 AM, the acetoxymethyl ester is cleaved by the cellular esterases and
allows the Fura-2 to bind cytosolic Ca2+. The emission intensity and the spectrum shift of the
Fura-2 differ according to the amount of bound Ca2+. After excitation at 340 and 380nm, the
emission is collected at 510 nm. Appling ratiometric analysis for the collected emission at 340
and 380 potentially improves the sensitivity of the Ca2+ imaging and overcomes the loading
errors and background noise (Chen et al., 2006; Vortherms et al., 2011).
The mitochondrial membrane potential (MX) is a potential indicator of mitochondria
soundness and its membrane integrity; MX deviations are a strong indicator of apoptosis.
Tetramethylrhodamine ethyl ester (TMRE) is a permeable fluorescent dye that reversibly binds
the negatively charged mitochondrial membrane. Measuring the emission intensity of the bound
TMRE in mitochondrial membranes versus the background is used to determine MX. Upon a
change in the MX, the TMRE dissociates from or associates back into the mitochondrial
membrane, resulting in an overall change in TMRE fluorescence. TMRE is excited at 548 nm,
and the emission is collected at 575 nm (Bernas and Dobrucki, 2002; Farkas et al., 1989;
O’Reilly et al., 2003).
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3.2
3.2.1

Materials and Methods:
Fura-2 Calcium Imaging:

The cells were cultured in 35 mm plates at a seeding density of 0.3 x 106 in 2 mL of
medium. After 24 h incubation in standard condition, the media was removed, and new 2 mL of
loading medium containing Fura-2 AM (Fura-2-acetoxymethyl ester, Molecular Probes®,
Eugene, OR, USA) at concentration of 5 µM and 0.02 % Pluronic F-127 (Invitrogen®, Thermo
Fisher Scientific) was added. The cells were incubated for 45 minutes in standard condition for
loading the Fura-2 AM into the cells. After incubation, the cells were washed with an
extracellular solution (ECS) 3 times, then 4 mL of ECS was added to the plate. The plate was
kept in the dark at room temperature for 45 minutes for cleaving the acetoxymethyl groups of the
Fura-2 AM by cellular esterases.
Time-lapse Ca2+ imaging was performed using an Olympus IX70 inverted microscope
equipped with phase contrast optics and a cooled CCD camera. Fura-2 was excited at 340 and
380 nm (8% intensity), and the emission was collected at 510 nm at each excitation wavelength.
The emission intensities obtained at excitation wavelength of 340 and 380nm were ratioed to
determine the [Ca2+]i. The cells were imaged for 4 minutes to obtain a baseline of [Ca2+]i, upon
which the treatment was added and cells imaged for an additional ~40 minutes. The regions of
interest (ROIs) were adjusted such that at least 5 cells were imaged simultaneously, and the assay
was at least repeated twice.

3.2.2

Mitochondrial Membrane Potential Assay:

The cells were cultured in 35 mm plates at a seeding density of 0.3 x 106 in 2 mL of
medium. After 24 h incubation in standard condition, the media was removed, and new 2 mL of
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loading medium containing 200 nM of TMRE (Molecular Probs®, Eugene, OR, USA) was
added. The cells were incubated for 30 minutes in standard condition for loading the TMRE into
the cells. After incubation, the cells were washed with ECS 3 times, then 4 mL of ECS was
added to the plate. The plate was kept in the dark at room temperature for 15 minutes for
stabilizing the TMRE bound into the mitochondrial membrane. Time-lapse TMRE imaging was
performed using an Olympus IX70 inverted microscope equipped with phase contrast optics and
a cooled CCD camera. TMRE was excited at 548 nm (6-8 % intensity), and the emission was
collected at wavelength 575. TMRE emission was analyzed ratiometrically against the
background to determine the mitochondrial membrane potential (MX). The cells were imaged
for 4 minutes to obtain a stable baseline reading for the MX, after which the treatment was
added, and cells were imaged for an additional ~40 minutes.

3.2.3

Statistical Analysis:

GraphPad Prism 6 software was used for data plotting, graphing, and statistical analysis.
The graphs showed the points representing the average response versus time and the connecting
line. Results are expressed as mean±SE (standard error). The results were calculated using
Microsoft excel to obtain the percentage of change. The percentage of change was plotted using
GraphPad Prism 6 column analysis and expressed as mean±SE.
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3.3
3.3.1

Results:
The Effect of MBF on Cytosolic Calcium Concentration [Ca2+]i:

Initially, the effect of DMSO on the [Ca2+]i was measured using the Fura 2 calcium
imaging, because all the drugs used were dissolved in DMSO. Treating the cells with DMSO
equal to the concentration used for dissolving the drugs did not change the intracellular [Ca2+]i
as indicated by the constant 340/380 fluorescence ratio of Fura-2 AM before and after adding of
DMSO (Figure 3, A). Treating CFPAC-1 cells with MBF at a dose equal to the IC50 (6 μM)
caused ~ 350% increase in the [Ca2+]i in comparison to the baseline obtained before adding the
MBF (Figure 3, B; Figure 5). Also, treating HCC-1806 cells with 8 μM of MBF (equal to IC50)
resulted in ~ 110% increase in the [Ca2+]i (Figure 3, C; Figure 5). Interestingly, MBF
administration at a dose of 0.98 μM into CFPAC-1 cells did not increase the [Ca2+]i (Figure 3,
D).

3.3.2

Determine the Mechanism of Increasing the Cytosolic Ca2+ Concentration by

MBF:
To determine if the increase in [Ca2+]i resulted from Ca2+ influx across the plasma
membrane from the extracellular medium, Fura-2 calcium imaging of CFPAC-1 cells was
repeated in calcium-free ECS to eliminate the calcium gradient across the plasma membrane.
Administration of MBF at a dose of 6 μM in calcium-free ECS still resulted in ~ 100% increase
in the [Ca2+]i (Figure 4, A), suggesting that some of the increase in [Ca2+]i seen in response to
MBF above was not caused by Ca2+ influx, but instead was likely due to release from
intracellular stores. To test whether the ER might be a source of Ca2+ release, MBF treatment
was next repeated on cells in which the ER had been previously emptied, with the rationale that
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MBF should no longer be able to trigger a Ca2+ release from the ER. Therefore, CFPAC-1 cells,
in normal Ca2+ containing ECS, were pretreated with the SERCA pump inhibitor Thap for 13
minutes, followed by the application of MBF. Pre-administration of Thap at a concentration of
10 μM to CFPAC-1 cells fully blocked the effect of MBF on increasing the [Ca2+]i suggesting
that the Ca2+ increase elicited by MBF treatment was via release from the ER (Figure 4, B).
Interestingly, Thap administration by itself transiently increased the [Ca2+]i. Taken together the
administration of MBF at a dose equal to the IC50 caused more than 100% increase of [Ca2+]i in
both HCC-1806 cells and CFPAC-1 cells, even in calcium-free ECS, whereas Thap blocked the
[Ca2+]i increase induced by MBF (Figure 5). The peak of [Ca2+]i increase was ~ 350% in
CFPAC-1 cells and ~ 110% in HCC-1806 cells that treated with MBF in normal Ca2+ containing
ECS, whereas it was ~ 100% in CFPAC-1 cells that treated with MBF in Ca2+ free ECS. Those
variations in the peak might be due to the natural differences between the cells that originated
from pancreatic cancer (CFPAC-1) and breast cancer (HCC-1806). In addition to the CFPAC-1
cells contain mutant cystic fibrosis (CF) gene that modifies the structure of the ER (Antigny et
al., 2011; Schoumacher et al., 1990). Moreover, the differences between the cells age and the
temporal functions when the assay was being conducted might affect the amount of Ca2+ stored
in ER that have a wide range from 103- to ~104 times the [Ca2+]i (Samtleben et al., 2013).
Further, washing the cells with Ca2+ free ECS and keeping them in it decreased the overall
availability of Ca2+ that normally perform highly dynamic movement between the extracellular
environment, cytosol, and cell compartments according to the temporo-spatial signal.
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Figure 3 MBF in Doses Equal to IC50 Induced [Ca2+].
Figure 3: Fura-2 Ca2+ imaging for detecting the effect of the MBF on [Ca2+]i. (A) The
DMSO administration to CFPAC-1 cells in a concentration equal to the one used for dissolving
the drugs did not induce any change in fluorescence ratio, which indicates unchanged [Ca2+]i. (B)
Administration of MBF in IC50 dose (6 μM) to CFPAC-1 cells significantly increased the [Ca2+]i.
(C) Also, Administration of MBF in IC50 dose (8 μM) to HCC-1806 cells caused the same effect
in increasing the [Ca2+]i. (D) Administration of MBF at a dose of 0.92 μM showed no effect on
the [Ca2+]i.
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Figure 4 MBF-Induces Ca2+ Release form ER.

Figure 4: Further Fura-2 assays using CFPAC-1 cells for indicating the mechanism of
[Ca2+]i increase associated with MBF treatment. (A) The administration of 6 μM of MBF in the
presence Ca2+ free ECS resulted in an increase of [Ca2+]i, although it was smaller than in the
presence of normal extracellular Ca concentration (B) The pre-administration of Thap at a
concentration of 10 μM to empty the ER Ca2+ store blocked the MBF-induced [Ca2+]i increase.
MBF was added 13 minutes after pre-administration of Thap, after the [Ca2+]i had almost
returned to pretreatment concentrations.
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Figure 5 Percentage increase of [Ca2+] in CFPAC-1 and HCC-1806 cell lines in response to
MBF adminstration

Figure 5: In-vitro administration of MBF at a dose of 6 μM to the CFPAC-1 cells in
normal Ca2+ containing medium induced ~ 350% increase in the [Ca2+]. Likewise, treating
CFPAC-1 cells in Ca2+ free ECS with the same concentration caused ~ 100% increase in the
[Ca2+]. The difference in % increase between the two previous assays might be due to the overall
scarcity of Ca2+ associated with using Ca2+ free ECS in washing the cells and during imaging.
Whereas, administration of MBF at a dose of 8 μM to the HCC-1806 cells in normal Ca2+
containing medium induced ~ 110% increase in the [Ca2+]. The difference in % increase between
the two cell lines might be due to the natural differenace between CFPAC-1 cells and HCC-1806
cells that they orgianted from pancreatic and breast cancer cells respectively. In addition to
CFPAC-1 cells includes CF mutant gene that alters the ER structure.
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3.3.3

The effect of MBF Administration on Mitochondrial Membrane Potential

(MX):
The previous results showed that MBF-induced more than a 100% increase in the [Ca2+]i.
To determine whether the change in intracellular Ca2+ had an effect on mitochondrial function,
the MX in response to MBF treatment was measured using TMRE. Initially, CFPAC-1 cells
were treated with DMSO in the concentration used for dissolving the drugs. Administration of
DMSO had no effect on the TMRE fluorescence ratio (F/F0) when compared to baseline levels
obtained before the administration of DMSO. MBF administration to CFPAC-1 cells at a dose
equal to IC50 (6 μM) caused a strong hyperpolarization of the MX due to ~ 57% shifting in the
MX toward the negative side, followed by a small depolarization due to ~ 8% shifting in the MX
toward the positive side after returning back to the baseline levels obtained before the
administration of MBF (Figure 6, A-B). Measuring the MX of HCC-1806 cells using the same
protocol showed a small hyperpolarization of the MX due to ~ 3% shifting in the MX toward the
negative side, followed by a strong depolarization due to ~ 31% shifting in the MX toward the
positive side after returning back to the baseline levels obtained before the administration of
MBF. The administration of the same concentration of DMSO to HCC-1806 cells did not impact
the MX (Figure 6, C-D). Suggesting that the effect of MBF on MX seen in response to MBF
above was triggered by MBF-induced Ca2+ release from the ER. To test whether the Ca2+
released from the ER in response to MBF administration might be required for inducing a change
in MX, TMRE was next repeated on cells in which the ER had been previously emptied by Thap
pretreatment, with the rationale that MBF should no longer be able to trigger a change in MX.
Therefore, CFPAC-1 cells were pretreated with Thap at a dose of 10 μM for 20 minutes,
followed by the application of MBF at the IC50 dose, 6 μM. Pre-administration of Thap to
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CFPAC-1 cells fully blocked the MX hyperpolarization associated with MBF administration
suggesting that the MBF-induced Ca2+ release from the ER Ca2+ was essential for MX
hyperpolarization elicited by MBF treatment. Interestingly, Thap administration by itself caused
MX depolarization, whereas, the rate of depolarization is increased with MBF later
coadministration (Figure 6, E). Taken together, applying MBF to cancer cells induced
hyperpolarization of the MX followed by depolarization that varies in the degree of shift from
the normal MX. Pre-administration of Thap to CFPAC-1 cells completely blocked the MX
hyperpolarization induced by MBF. Whereas, coadministration of Thap with MBF boosted the
MX depolarization response (Figure 6, F).
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Figure 6 MBF in doses equal to IC50 induces MX hyperpolarization.
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Figure 6: (A) DMSO administration to CFPAC-1 cells did not impact the MX, as
evidenced by the flat baseline levels recorded before and after addition of DMSO. (B) Treating
the CFPAC-1 cells with 6 μM of MBF (equal to IC50) caused a strong hyperpolarization of the
MX by shifting in the MX ~ 57% toward the negative side, followed by a small, depolarization
by 8% shifting in the MX toward the positive side after returning back to the baseline levels
obtained before the administration of MBF. (C) Administration of DMSO to HCC-1806 cells did
not result in a change of MX from pretreatment levels. (D) Treating the HCC-1806 cells with 8
μM of MBF (equal to IC50) induced a small hyperpolarization of the MX by shifting in the MX ~
3% toward the negative side, followed by a strong depolarization by 31% shifting in the MX
toward the positive side after returning back to the baseline levels obtained before the
administration of MBFE) Pretreatment of CFPAC-1 cells with Thap at a dose of 10 μM blocked
the hyperpolarization of MX induced by MBF. Thap caused MX depolarization by 23% shifting
in the MX toward the positive side that depolarization increase to 57% by adding MBF at a dose
of 6 μM. D) The % change of MX induced by MBF administration into CFPAC-1 and HCC1806 at a dose of 6, 8 μM respectively. The hyperpolarization effect showed as increase of the
column length toward the negative side of the Y axis (downward) and the depolarization effect
showed an increase of the column length toward the positive side of the Y axis (upward). Preadministration of the Thap in a dose of 10 μM blocked the hyperpolarization resulted from MBF
administration and strengthened the depolarization effect
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3.4

Discussion:

To determine the effect of MBF on the Ca2+ signaling in CFPAC-1 and HCC-1806 cells,
the [Ca2+]i was determined after treating cells with previously established IC50 doses for MBF.
MBF was introduced into the market as antihypertensive drug that has a greater affinity to block
the TTCC over the LTCC , which inhibits Ca2+ induced Ca2+ release in cardiac and arterial
smooth muscles (Ottolia et al., 2013), Our results showed that MBF induces a [Ca2+]i increase in
cancer cells. The increased [Ca2+]i can originate from different sources. Ca2+ can enter the cells
from the extracellular environment or can be released from intracellular stores (ER and
mitochondria).
Initially, the intracellular [Ca2+]i increase was investigated using Ca2+ imaging. The
results indicated that treating the HCC-1806 and CFPAC-1 cells with the IC50 doses of MBF (8
and 6 µM respectively) increased the [Ca2+]i more than 100% within ~1.5 minute of MBF
administration. Furthermore, the Ca2+ imaging was repeated for identifying the mechanism by
which the MBF induces [Ca2+]i increase. Initially, the possibility of Ca2+ entrance from outside
the cell was examined by repeating the Ca2+ imaging using a Ca2+ free ECS. Administration of
MBF into CFOAC-1 cells in Ca2+ free medium induced ~ 100% increase in the [Ca2+]i, which
excluded the suggestion that the increase of [Ca2+]i induced by MBF was due to the influx of the
Ca2+ from the extracellular environment. Excluding the extracellular Ca2+ source left us with two
other possibilities, namely that MBF-induced Ca2+ release from the ER or the mitochondria,
which are the major cytosolic Ca2+ stores.
For identifying the intracellular source of Ca2+ release caused by MBF administration, the
Ca2+ imaging was repeated using Thap pretreatment in a dose of 10 μM followed by adding
MBF at the IC50 dose. Interestingly, Thap treatment raised the [Ca2+]i and blocked the MBF-
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induced [Ca2+]i increase, when MBF was subsequently added to the cells after Thap
pretreatment. The Thap induced [Ca2+]i increase lasted for ~ 10-15 minutes and then returned
back to normal levels before adding MBF (Figure 4, B). Thap is a known SERCA blocker, which
normally pumps Ca2+ back into the ER; Thap treatment, therefore, resulted in emptying the ER
Ca2+ stores. This directly suggested that MBF-induced Ca2+ release from the ER. A similar effect
was reported in leukemia cell lines treated with MBF (Huang et al., 2015; Zhang et al., 2006).
The MBF IC50 doses used in Ca2+ imaging were reported to block most types of voltage
gated Ca2+ channels (L and TTCC) (Martin et al., 2000), voltage-gated Na+ channels (Eller et al.,
2000; McNulty and Hanck, 2004), and volume-activated Cl- channels (Nilius et al., 1997) and .
The blocking of TTCC that overexpressed in cancer cells in addition to multiple ion channels
affects the ionic homeostasis in cancer cells and might contribute to stressing the ER causing
Ca2+ release. Depletion of Ca2+ from the ER may severely impact Ca2+ dependent chaperones in
the ER, resulting in the accumulation of miss-folded protein in the ER that might trigger
apoptosis. Further, impacting the ER chaperones likely reduces the cell’s ability to produce
proteins and enzymes essential for maintaining cellular biological functions, especially in highly
active cancer cells (Coe and Michalak, 2009).
Treating CFPAC-1 cells with MBF concentrations < 1 µM did not induce Ca2+ release
(Figure 3, D), although a dose of 1 µM MBF is higher than the required for blocking TTCC.
Also, MBF at a concentration of 1 µM or less did not show any effect on cancer cells’ viability
in MTT assays. That suggests the MBF-induced Ca2+ release from the ER is required for
inhibiting the cancer cells’ viability Furthermore, the MBF concentrations ≤ 1 µM that able to
block the TTCC did not show any change in the [Ca2+]i suggesting that the MBF-induced Ca2+
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release from the ER was not resulting from blocking of TTCC. and that Ca2+ release not only
produced by blocking TTCC.
We suggested that the MBF-induced Ca2+ release from the ER might affect the
mitochondria through the mitochondria ER-associated membranes, which play a crucial role in
Ca2+ transport and signaling between the ER and mitochondria (Morciano et al., 2018).
Therefore, the effect of MBF was investigated as an indicator of the effect of MBF on the
mitochondrial soundness. Treating CFPAC-1 and HCC-1806 cells with MBF at the IC50 dose (6
and 8 µM respectively) showed MX hyperpolarization followed with depolarization.
Interestingly, pretreating the cells with Thap (10 µM) before MBF blocked the hyperpolarization
effect of MBF.
It is possible that MBF is disrupting the ER homeostasis that affects protein synthesis in
the ER and triggers the unfolded protein response. Consequently, the cells would suffer from
oxidative stress due to a leakage of reactive oxygen species (ROS) form the mitochondrial
electron transfer system, causing MX hyperpolarization. Eventually, the mitochondria would
collapse, and cells would undergo subsequent apoptosis. A similar effect was reported in
leukemia cells treated with ER stressors econazole and tunicamycin, but Thap showed neither
MX hyperpolarization nor ROS release (Zhang et al., 2006).
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3.5

Conclusion:

Treating cancer cells with the IC50 doses of MBF-induced ER Ca2+ release in cancer cells
and a more than 100% increase in [Ca2+]i, while using 0.92 µM of MBF did not show any change
in [Ca2+]i. Also, in-vitro administration of MBF affected the MX and caused MX
hyperpolarization followed by depolarization, which is considered as a pre-apoptotic sign. MBFinduced ER Ca2+ release was necessary to inhibit cancer cell viability and to impact the MX by
hyperpolarization.
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4- CHAPTER 3
MBF Induces Apoptosis via Releasing Ca2+ from Thapsigargin Sensitive Stores

4.1

Introduction:

The effect of anticancer drugs varies according to the mechanism of action. Because the
cancer cells exhibit uncontrolled proliferation, some effective anticancer drugs, especially the
chemotherapeutics, target the cell division machinery that inhibits cell division and triggers
apoptotic cell death. There are other targets for specific kinds of cancers, such as antiestrogenic
agents for treating estrogen sensitive breast cancer cells and targeting the lipid metabolism
(Ariazi et al., 2011; Daher et al., 1990; Saxena et al., 2017). Apoptosis is the final and desirable
endpoint for cancer cells after exposure to anticancer drug, because it is a normal process that
ends with breaking down the cell into apoptotic bodies, which are recognized and engulfed by
macrophages.
Apoptosis is defined as genetically programmed cell death that normally happens in
multiple life stages from embryonic development until aging and can also occurs under
pathological conditions. The term apoptosis is derived from the Greek and means ‘falling off’ as
in leaves falling off a tree, and indicates the phenomenon by which a cell enters its own
termination processes (Kerr et al., 1972).
Apoptosis is associated with many morphological changes, including abolishing the
membrane symmetry and attachment, blebbing of the plasma membrane, condensation of
cytoplasm and nucleus, and DNA internucleosomal cleavage. One of the earliest events of
apoptosis is the loss of plasma membrane symmetry. Thus, the phospholipid phosphatidylserine
(PS) is translocated from the inner leaflet of the plasma membrane into the outer leaflet and
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exposed to the extracellular environment. The exposed PS remains on the external leaflet of the
plasma membrane acting as a marker of the apoptotic cell or the broken down apoptotic bodies to
be identified and phagocytosed by macrophages.
The microscopic changes of an apoptotic cell can be distinguished in several stages.
Initially, in early apoptosis, cells shrink and become smaller in size, resulting in cytoplasm
condensation with tightly packed organelles. Also, the chromatin undergoes irreversible
condensation (pyknosis) at early apoptosis. Then, the plasma membrane shows extensive
blebbing, followed by destructive fragmentation of the nucleus (karyorrhexis) caused by
activated endonucleases. Eventually, the cell is fragmented into apoptotic bodies in a process
called “budding.” The apoptotic bodies include tightly packed organelles, with or without a
nuclear fragment, in an intact plasma membrane, where the integrity of organelles is still
conserved. Subsequently, the apoptotic bodies are phagocytosed by macrophages, parenchymal
cells, or neoplastic cells and undergo further degradation by phagolysosomes (Casciola-Rosen et
al., 1996; Elmore, 2007) (Figure 7).
Suggesting that MBF might induce apoptosis. The apoptosis assay was performed on
CFPAC-1 cells treated with MBF at the IC50 dose (6 μM) for 48 h and at higher concentrations
for 12 h to determine the MBF effect at time longer and shorter than doubling time. Furthermore,
to test whether MBF-induced Ca2+ release from the ER might be the trigger for the apoptosis,
MBF treatment was next repeated on cells in which the ER had been previously emptied by Thap
pretreatment, with the rationale that MBF should no longer be able to induce apoptosis.
Annexin V is a Ca2+- dependent phospholipid-binding protein and has a high affinity for
binding the exposed PS on the external surface of the apoptotic cell (Van Engeland et al., 1996;
Vermes et al., 1995). The fluorophore-conjugated Annexin V (e.g., Annexin V-FITC) can be
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detected by excitation-emission properties of the fluorophore. This technique can be used for
detecting and sorting apoptotic cells through flow cytometry with high sensitivity and accuracy.
Necrosis (from a Greek word meaning “death”) is a form of cell injury that results in
premature cell death in a living tissue, which usually happens by autolysis. Necrosis, in contrast
to apoptosis, is an abnormal condition mostly caused by an external factor that affects the cell or
tissue, such as toxins, infection, or trauma that triggers unregulated digestion of the cell
components and is associated with an inflammatory response. Also, necrosis differs
morphologically from apoptosis. The necrotic cell initially undergoes swelling, followed by
plasma membrane collapse and cell lysis (Proskuryakov et al., 2003) (Figure 6).
Propidium iodide (PI) is a fluorescent DNA intercalating agent that is widely used for
detecting necrotic cells. PI cannot enter through the intact plasma membrane of the healthy cells
or cells in the early to intermediate stages of apoptosis. Losing the integrity of the plasma and
nuclear membranes allows entrance of PI into the cell, resulting in the staining of DNA in the
case of necrosis and late apoptosis. The excitation-emission characteristics of PI can be used to
detect cells in late apoptosis and necrosis using the flow cytometry (Cummings et al., 2012).
The PS exposure in the apoptotic cell allows a prompt recognition by the phagocytes,
which achieve a quick phagocytosis with minimal complications for the surrounding tissue
(Bratton et al., 1997).
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http://digitalvortex.info/plasma-diagram-a2be12b02b/

Figure 7 The morphological changes of apoptosis versus necrosis.

Figure 7: The different morphological changes of a cell undergoing apoptosis or
necrosis. Apoptotic cell shows membrane budding and exposed PS on the extracellular side of its
membrane leaflets, increasing membrane permeability and cell shrinkage. Finally, the cell
undergoes fragmentation into apoptotic bodies that will be engulfed by macrophages. While the
necrotic cell shows swelling and loss of its membrane integrity initially, the cell will eventually
rupture with severe tissue reactions that induce an inflammatory response.
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4.2
4.2.1

Materials and Methods:
Apoptosis Assay:

CFPAC-1 cells were grown in 35 mm plates at a seeding density of ≃ 0.3 x 106 in 2 mL
of suitable medium. Various doses of MBF and different expousuer time were applied to
detrmine the MBF effect at time longer and shorter than doubling time. Further, to test whether
MBF-induced Ca2+ release from the ER might be the trigger for the apoptosis, MBF treatment
was next repeated on cells in which the ER had been previously emptied by Thap pretreatment
After 24 h incubation in standard conditions, one plate was treated with 6 µM of MBF (IC50
dose) and another plate with 6 µL of DMSO (control) for 48 h; One plate was treated for 12 h
using each of the following regimes, DMSO 0.1 % for 30 minutes then MBF 50 µM was added,
DMSO 0.1 % for 30 minutes then MBF 20 µM was added, Thap 10 µM for 30 minutes then
DMSO 0.2 % was added, Thap 10 µM for 30 minutes then the MBF 20 µM was added, Thap 10
µM for 30 minutes then the cells were washed with 1x DPBS followed by adding MBF 20 µM,
and the control was treated with DMSO 0.3%. Further, three untreated plates were kept for flow
cytometer controls. The cells were detached from the plate by adding 0.7 mL of trypsin 0.25 %
(Corning®) for 6 minutes then 0.6 mL of medium containing 10 % FBS was added for stopping
the effect of trypsin. The cells were pelleted using centrifugation at 120 xg for 5 minutes, then
the medium was removed, and the cells were washed with DPBS and re-pelleted. The
TACS® Annexin V-FITC Kit (Trevigen Inc, MD, USA) was used for apoptosis and necrosis
detection. The cells were resuspended and stained with Annexin V-FITC and Propidium Iodide
according to the kit's protocol. The three non treated plates were kept for assigning the standards
of the flow cytometer machine and treated as follows: non-stained, only Annexin V-FITC
stained, and only Propidium Iodide stained. The cells were screened by BD LSRFortessaTM
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(BD Biosciences, CA, USA). The flow cytometry data were analyzed using FlowJo software
(FlowJo LLC, OR, USA). The data obtained from the FlowJo software were expressed as
percentage of the cells in each status (early apoptosis, late apoptosis, and necrosis). The
calulations for removing the percentage of cells affected by DMSO were prformed by Microsoft
Excel and the final data were analyzed and plotted using GraphPad Prizm 6. The assay was run
for 10000 cells for the machine controls and 30000 cells for the DMSO controls and treated
cells.
4.2.2

Statistical Analysis:

GraphPad Prism 6 software was used for data plotting, graph building, and statistical
analysis. The data were calculated with Microsoft Excel, then fitted using the GraphPad column
analysis as a percentage of the overall population, which was 104 cells for controls and 3 x 104
for treated cells.

4.3
4.3.1

Results:
AnnexinV/PI Assay for Detection of MBF-Induced Apoptosis and the Role of

MBF-Induced Ca2+ Release in the Apoptosis of CFPAC-1 Cells:
Exposure of the phosphatidylserine (PS) in the external leaflet of the plasma membrane
during the early and intermediate stages of apoptosis can be detected by annexin V conjugation.
Also, the apoptotic bodies and microparticles are stained with the annexin V (Hristov et al.,
2004). The highly fluorescent annexin V bound to the exposed PS was excited at ~ 490 nm and
emission was collected at ~ 490-535 nm. Necrotic and the late apoptotic cells would lose their
membrane integrity, resulting in the diffusion of PI stain into the cells where it would stain
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necrotic cell nuclei due to its DNA intercalating capacity. PI can subsequently be detected by
exciting it at ~ 490 nm and collecting the emission at ~ 535-620 nm.
Treating CFPAC-1 cells with the MBF IC50 dose (6 µM) for 48 h increased the number
of cells that expressed apoptotic markers by 9% (apoptosis 2%, and late apoptosis 7%) versus
DMSO control (Figure 8, D, E, L). Furthermore, exposing CFPAC-1 cells to 50 µM of MBF for
12 h dramatically increased the expression of cells with apoptotic markers to 43% (almost no late
apoptosis or necrosis, 2%) versus DMSO control (Figure 8, F, G, L). Moreover, MBF
administration at a dose of 20 µM for 12 h significantly increased the number of cells with
apoptotic markers up to 38% versus DMSO control, but most of those cells were in the late
apoptosis phase (30% of 38%) (Figure 8, F, H, L). Also, Treating the cells with 10 µM of Thap
for 12 h induced apoptosis only for 11% of cells (apoptosis 8%, and late apoptosis 3%) (Figure
7, F, I, L). Interestingly, pretreating the cells with 10 µM of Thap for 30 minutes then adding 20
µM of MBF and keeping them together for 12 h decreased the number of cells with apoptotic
markers from 38% (MBF only) to 15%. Furthermore, the cells with MBF only treatment showed
late apoptosis (30%) more than early and intermediate apoptosis (8%), while the combination
treatment with Thap and MBF showed opposite results (apoptosis 11%, and late apoptosis 4%)
(Figure 8, F, J, L). Whilst, washing out the Thap after pretreating the cells for 30 minutes then
adding MBF alone for 12 minutes also reduced the number of cells with apoptosis markers to
22% (apoptosis 10%, and late apoptosis 12%) versus 38% in MBF only treatment (Figure 8, F,
K, L). Thus, removing Thap after 30 minutes of treatment brought back the strong apoptotic
action of MBF but still less than the effect of sole administration of MBF (Figure 8, L).
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Figure 8 MBF-induced apoptosis in CFPAC-1 cells via Ca2+ release from Thap sensitive stores.

Figure 8: Detection of MBF-induced apoptosis in CFPAC-1 cells using AnnexinV/PI
staining and flow cytometry the degree of AnnexinV-FITC expression was plotted on the X,
while the PI expression was plotted on the Y axis. (A-C) Non-treated machine controls; the cells
in (A) were not stained, while the cells in (B) and (C) were stained with AnnexinV and PI
respectively. The controls were run for adjusting the gates’ voltages that dependently controls the
wavelength of maximum emission. (D- E) Treating cells with MBF at a dose of 6 µM for 48 h
showed 9% increase in cells with apoptotic markers versus DMSO treated control cells. (F, G)
The single treatment of CFPAC-1 cells with MBF showed a significant increase in the cells that
express apoptosis markers versus DMSO treated control cells; this increase showed dosedependency (38% and 43% for MBF 20 and 50 µM, respectively). (H) Cells that were treated
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with 10 µM of Thap showed expression of apoptosis markers in 11% of cells. (I- K) Pretreating
the cells with 10 µM of Thap decreased the apoptotic effect of MBF. Coadministration of MBF
and Thap for 12 h, by adding 10 µM of Thap for 30 minutes prior to adding 20 µM of MBF to
CFPAC-1 cells markedly decreased the percentage of cells expressed apoptosis to 15% versus
38% with MBF single treatment. Whereas, washing the cells with DPBS after pretreating the
cells with 10 µM of Thap for 30 minutes and prior to administrating of 20 µM of MBF alone for
12 h partially restored the apoptotic effect of MBF and mitigated the apoptosis blockage effect of
Thap, 22% of cells expressed apoptosis versus 38% with coadministration of MBF and Thap
together for 12 h. (L) The column graph summarizes the results of the apoptosis assays. Treating
CFPAC cells with MBF resulted in a dose-dependent expression of apoptosis markers that varied
from early to intermediate apoptosis, and to late apoptosis. A single administration of 10 µM of
Thap significantly inhibited the apoptotic effect of MBF.

4.4

Discussion:

As indicated in chapter 1, MBF potentially inhibited different cancer cells’ viability at
low concentrations. Conducting a MTT assay over 48 h of treatment allowed enough time for the
cells to perform one to two replication cycles that also allowed MBF to impact the viability of
the cells or halt their division or both. To test whether the inhibitory effect of MBF on the cancer
cells caused by inducing apoptosis or necrosis, apoptosis assay was conducted.
An apoptosis assay was performed in order to investigate the apoptotic effect of MBF on
CFPAC-1 cells. It is important to note that the desirable outcome of an anticancer drug in this
context was to induce apoptosis, thereby triggering programmed cell death without adverse
tissue reaction or inflammation commonly seen during necrotic cell death. The highest
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concentration of MBF (50 µM) showed massive apoptotic effect (43%) after 12 h of treatment
that can be identified as very fast early apoptosis. Treating the cells with MBF at a dose of 20
µM induced apoptosis in 38% of cells, and most of the cells showed late apoptosis (30%). Taken
together, raising the dose of MBF up to 50 µM accelerated the apoptosis until the cells
completely disintegrated into apoptotic bodies. The membranes of the apoptotic bodies, which
are parts of the apoptotic cell membrane, contain externally exposed PS, therefore they were
stained with Annexin V-FITC. While apoptotic bodies do not include nuclei or even intact DNA
that they could not be stained with PI. Consequently, Apoptotic bodies expressed Annexin VFITC stain only and were showed by the flow cytometer on the X axis similar to the early
apoptosis (Hristov et al., 2004).
Further, it was shown that late apoptosis was predominant at lower concentration of MBF
(Figure 8), suggesting a later onset of apoptosis. Interestingly, Thap coadministration with MBF
mitigated the apoptotic effect of MBF. Pretreating the cells with Thap at a dose of 10 µM, then
keeping Thap with MBF (20 µM) as a combination for 12 h, decreased the apoptotic effect of
MBF by 61%. Interestingly, transient pretreatment of cells with Thap for 30 minutes, followed
by removal of Thap and addition 20 µM of MBF alone for 12 h resulted a lower degree of
apoptosis inhibition (42%) than when Thap and MBF were coadministered (61%).
Thap is a SERCA pump inhibitor that prevents the Ca2+ reuptake by the ER, resulting in
emptying of Ca2+ stored in the ER. Thap is an ER stressor that could induce apoptosis in small
fraction of the cells, only 2%, after 12 h of treatment with a dose of 10 µM. The results
suggested that emptying the Ca2+ stores in the ER may potentially diminish the MBF-induced
apoptosis in cancer cells, pointing towards the importance of MBF-induced Ca2+ release for the
ER for killing of CFPAC-1 cancer cells.
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4.5

Conclusion:

MBF induces apoptosis in CFPAC-1 cells in a dose dependent fashion. MBF
administration to CFPAC-1 cells at IC50 dose (6 µM) caused little apoptotic effect (9%); while a
dose of 50 µM induced massive and fast apoptosis (43%). Further, MBF at a dose of 20 µM
generated significant apoptosis (38%), which was diminished by Thap coadministration.
Inhibiting the ER Ca2+ reuptake by Thap blocked the MBF-induced apoptosis, which suggests
that the ER Ca2+ store is important for maintaining the strong apoptotic effect of MBF.
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5- CHAPTER 4
THE ROLE OF INTRACELLULAR CALCIUM RELEASE FROM ER IN
MIBEFRADIL EFFECTS TO LIPID METABOLISM

5.1

Introduction:

Lipid droplets (LDs) are the principal cellular organelles for lipids storage that either are
acquired from the nutrition or produced by the cell during the normal metabolism. Excessive
lipid storage in the form of LDs is associated with the pathogenesis of many diseases, such as
atherosclerosis, obesity, and diabetes. Therefore, studying the structure-function and biological
dynamics of the LDs on the cellular level is of great interest. Furthermore, the latest studies not
only investigate LDs dynamics but also try to correlate changes in LD with those in other
organelles [e.g., peroxisomes, endosomes, endoplasmic reticulum (ER), plasma membrane and
mitochondria] (Guo et al., 2009).
The final synthesis of LDs is performed in the ER due to the presence of the final step
enzymes (mainly diglyceride acyltransferase, DGAT) of the synthetic pathways that mediate the
formation of neutral lipids (particularly triacylglycerols and steryl esters.) The saturation level of
the lipid pool within the ER membrane bilayer controls the release of the lipids by budding
toward the cytosolic side. The cell can utilize the lipids stored in LDs under starvation
circumstances through autophagy in a process involving autophagic proteins (Atgs) (Hashemi
and Goodman, 2015).
Multiple genes encoding for enzymes contributing in fatty acid and cholesterol
biosynthesis are targets of SREBPs (sterol regulatory element-binding proteins), which are a
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family of transcriptional factors that are fundamental for maintaining lipid homeostasis in
healthy cells (Bengoechea-Alonso and Ericsson, 2007).
Abnormal activation of SREBPs can be involved in many diseases such as fatty liver,
obesity, and insulin resistance and could contribute to cancer development (Shao and
Espenshade, 2012).
SREBPs are synthesized in the ER as inactive precursors and stay in the ER membrane in
association with SREBP-cleavage-activating protein (SCAP) and activated in response to a low
level of cholesterol or membrane phosphatidylcholine. Further, SREBPs contribute to the
downstream regulation of growth signaling through the PI3K (phosphatidylinositol-3-kinase)
pathway.
The ability of the cancer cells to perform a high rate of lipid production by de novo
lipogenesis was shown. Further, the rate of de novo lipogenesis was correlated with the tumor
stage, in that early stages showed a higher rate of lipogenesis. The high rate of lipogenesis is
required for the cancer cells for the formation of the phospholipids blocks for new cell
membranes, as a source of energy storage, and for lipid signaling, especially the growth factor
signaling that depends on PI3P (phosphatidylinositol (3,4,5)-trisphosphate) and PI3K (Baenke et
al., 2013).
Furthermore, the overexpression of hypoxia-inducible factors (HIFs) due to the activation
of oncogenes and the hypoxia associated with the cancer mass was identified to enhance the lipid
biosynthesis (Santos and Schulze, 2012).
The altered lipid metabolism, including a high lipogenesis rate, was found to contribute
to cancer cell growth, proliferation, energy homeostasis, resistance to oxidative stress, resistance
to energy stress, and signaling functions of lipids. Therefore, tackling the lipid metabolism in
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cancer cells has emerged as a promising target for novel anticancer drugs (Menendez and Lupu,
2007; Santos and Schulze, 2012; Saxena et al., 2017).
In response to nutrient starvation, cancer cells can utilize the lipid stored in LDs by
recruiting the autophagic machinery, including autophagy related 5 (Atg5) protein (Baenke et al.,
2013). This lipid mobilization mechanism was consequently called ‘macrolipophagy’. Therefore,
the accumulation rate of LDs increased when macrolipophagy was suppressed. (Singh et al.,
2009).
The LDs within cells can be preserved through gentle? fixation using formaldehyde
(10%) and then stained with oil red O, which is a fat-soluble red stain. To achieve a quantitative
estimation of the amount of oil red O stained LDs in an area of interest, the cytoplasm and nuclei
are stained with a water-soluble hematoxylin dye that gives them a blue color (Light blue for the
cytoplasm and dark blue for the nucleus). Using a digital microscopic imaging approach, LDs
staining can be quantified against the whole cell area as a background (Fukumoto and Fujimoto,
2002; He et al., 2004).
Glycerol is produced by cells as a by-product of lipolysis whereas the cells utilize the lipid stores
upon need. Cells recruit lipolytic enzymes to break down the lipid stored in LDs into fatty acids
and glycerol. The glycerol produced by the cells grown in a cell culture dish will diffuse outside
of the cells and accumulate in the medium (Smith et al., 1979).
Glycerol Kinase (GK) exploits ATP into ADP for phosphorylating the glycerol producing
G-1-P (glycerol-1-phosphate). Consequently, GPO (glycerol phosphate oxidase) oxidizes G-1-P
to DAP (dihydroxyacetone phosphate) and hydrogen peroxide (H2O2). The H2O2 is coupled with
ESPA (4-aminoantipyrine (4-AAP) and sodium N-ethyl-N-(3-sulfopropyl) m-anisidine) to form
a quinoneimine dye by POD (peroxidase). The OD of the produced quinoneimine dye can be

55

measured at 540 nm as an indicator of the glycerol concentration and to be quantified against
standards with known glycerol concentration (Barham and Trinder, 1972; Trinder, 1969).
To test whether MBF might affect the lipid metabolism, oil red O stain and lipolysis
assay were performed on cancer cells treated with MBF, with the rationale that LDs number and
lipolysis rate should be impacted by MBF treatment due to its previously identified effect on
Ca2+ signaling, ER Ca2+ stores, and mitochondria that all fundamentally contribute to lipid
metabolism in cancer cell.

5.2
5.2.1

Materials and Methods:
Oil Red O Stain and Imaging:

The cells were grown in 35 mm plate at a seeding density of ≃ 0.3 x 106 and 0.8 x 106
Cells/ plate for CFPAC-1 and HCC-1806 cells, respectively. After 24 h incubation in standard
condition, the medium was replaced with medium contains MBF at the IC50 (6 and 8 µM,
respectively) for treated plates or DMSO for control plates. The plates were incubated for 1, 3, 6,
12, 24, 36 h in standard condition, 2 plates for each time point (treated and control). At each time
point, the medium was removed, and the cells were washed twice with 1x DPBS. The cells in
each plate were fixed with 1 mL of 10% formaldehyde for 30 minutes, then were washed twice
with deionized water. The fixed cells were treated with 1.5 mL of 60% isopropanol for 5
minutes. After isopropanol removal, 1.5 mL of 60% oil red O stain working solution was added
for 20 minutes for staining the lipid droplets. The stained cells were washed with deionized water
until the water rinsed off clear. For staining the cytoplasm and nuclei in blue, the cells were
treated with 1.5 mL hematoxylin for 1 minute then to be washed with deionized water until the
water rinsed off clear. All the staining procedures were done at room temperature.
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Using a ZEISS Axio Imager A1 polarized light microscope equipped with AxioCam
MRc 5 camera and connected to Zeiss AxioVision Rel. 4.8 software, the cells were imaged at
1000x total magnification (100x oil objective lens). All plates were imaged in the same manner;
10 images were taken from each plate, starting in the upper half of the plate from left to right,
then the lower half from right to left, and one image from the center (Figure 9). The images were
digitally analyzed using ImageJ software. The ImageJ ratiometric analysis was based on
detecting the intensity of the red color (lipid droplets) to blue color (the cytoplasm and the
nucleus). The red over blue ratios of the MBF treated cells versus DMSO treated control cells
were statistically analyzed to identify the percentage change of the amount of lipid droplets per
cell.

5.2.2

Glycerol Assay:

For detecting the MBF-induced lipolysis in CFPAC-1 cells, a Glycerol assay kit (SigmaAldrich) was used for colorimetric detection of the glycerol amount in the medium after MBF
treatment. The CFPAC- 1 cells were seeded at a density of ~ 0.5 x 106 cells in 1 mL of suitable
medium per well into 12 well plates. After 24 h incubation in standard conditions, column 1 (N =
4) was consecutively treated with medium contains DMSO 0.3% (-ve control), column 2 was
pretreated with DMSO 0.1 % for 30 minutes then MBF 20 µM was added, column 3 was
pretreated with Thap 10 µM for 30 minutes then DMSO 0.2 % was added, column 4 was
pretreated with Thap 10 µM for 30 minutes then the MBF 20 µM was added, and column 5 was
pretreated with Thap 10 µM for 30 minutes then the cells were washed with 1x DPBS followed
by adding MBF 20 µM. After incubating the plates in standard conditions for 12 h, the medium
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was collected in autoclaved 1.7 mL Eppendorf tubes and centrifuged at 8000 × g, and the
supernatant was stored at -80 oC.
The samples were transferred into 96 well plates (Corning®), and the glycerol assay was
performed according to the company's manual. The ODs were read for individual wells using a
microplate reader at wavelength 570 nm.

5.2.3

Statistical Analysis:

GraphPad Prism 6 software was used for data plotting, graphing, and statistical analysis.
ANOVA and t-test (non-paired) were used to analyze the statistical significance of the data. The
curves were fitted using GraphPad column analysis. Results are expressed as mean±SE (standard
error). Statistically, the P values for significant differences were indicated as follows: nonsignificant (ns) (P > 0.05), * (P ≤ 0.05), ** (P ≤ 0.01), *** (P ≤ 0.001), and **** (P ≤ 0.0001).
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10

Figure 9 Oil Red O imaging technique.

Figure 9: The 35 mm oil red O stained plate was imaged at 1000x total magnification
(100x oil objective lens) using a polarized light microscope. For each plate, 10 fields were
assigned starting in the upper half of the plate from left to right, then the lower half from right to
left, and one field from the center. The 10 images from each plate underwent ImageJ radiometric
analysis based on detecting the intensity of the red color (lipid droplets) to blue color (the
cytoplasm and the nucleus).
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5.3
5.3.1

Results:
Time-Dependent Changes in LDs Upon MBF Treatment with IC50 Dose:

The ImageJ digital analysis was performed for oil red O stained HCC-1806 cells treated
with the IC50 dose of MBF (8 µM) versus DMSO treated cells. The analysis showed a significant
decrease in the red (LDs) over blue (cytoplasm and nucleus) ratio in 3, 6, 12, 24, 36 h of
treatment, which indicates a decrease in the LDs number and/or volume. Treatment of HCC1806 cells for 1 h did not show a significant difference (Figure 10, A, B). In CFPAC-1 cells
treated with 6 µM of MBF, the analysis of oil red O staining showed a significant decrease in the
red over blue ratio after 12, 24, 36 h of treatment versus the DMSO treated control cells, whereas
there was no significant change in the red over blue ration after 1, 3, 6 hrs. of treatment (Figure
10, C, D).

5.3.2

The Effect of MBF on the Rate of Lipolysis in CFPAC-1 Cells:

The oil red O stain indicated a decrease in the LDs after MBF treatment. To investigate
whether MBF-induced lipolysis, the glycerol concentration was measured in the cells’ medium
after MBF treatment as an indicator of lipolysis. Treating CFPAC-1 cells with MBF in a dose
equal to the IC50 (6 µM) resulted in a significant increase in the glycerol concentration compared
to the DMSO treated control cells, but only after 36 h of treatment (Figure 11, A); other
treatment time points did not show any significant changes in glycerol concentration. Suggesting
that MBF might induce lipolysis that triggered by the MBF-induced Ca2+ release from the ER
Ca2+ stores. MBF treatment was next repeated on cells in which the ER had been previously
emptied by Thap, with the rationale that MBF should no longer be able to induce lipolysis.
Treating cells with 20 μM of MBF for 12 h did not result in a change in the glycerol
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concentration and pretreating the cells with Thap then combining MBF did not show difference
in the glycerol conc, as well; the amount of glycerol produced by the cells after 12 h of treatment
remained the same as in control (DMSD treated) cells for all treatment regimes except MBF at a
dose of 50 μM. Only the cells treated with 50 µM of MBF showed significant increases in
glycerol conc (Figure 11, B).
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Figure 10 MBF decreased the abundance of LDs in HCC-1806 and CFPAC-1 cells.
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Figure 10: (A) Oil red O stain of HCC-1806 cells after MBF treatment at the IC50 dose
(8 μM) at different time points showed a significant decrease of the red over blue intensity at 3,
6, 12, 24 and 36 h of treatment. (B) Selected images from the MBF treated HCC-1806 cells at
different time points. Images were captured using an inverted microscope with total
magnification power 1000 x. (C) The oil red O stain of CFPAC-1 cells after time point treatment
of MBF at the IC50 dose (6 μM) shows a significant decrease of the red over blue intensity at 12,
24 and 36 h of treatment. The decrease in red over blue intensity indicates a reduction in the LDs
size and/or numbers. (D) Selected images from the MBF treated CFPAC-1 cells at different time
points. Images were captured using an inverted microscope with total magnification power 1000
x.

64

G ly c e r o l C o n c e n t r a tio n in C F -P A C -1 M e d iu m

G l y c e r o l C o n c e n t r a t io n in C F - P A C - 1 M e d iu m A f t e r T h a p
a n d M B F In d i v id u a l a n d C o m b in e d T r e a t m e n t f o r 1 2 h

50

M
B
M
>
h

a

a
h
T

T

h

p

a

1

p

0

1

0

M

>

M

W

>

D

+

s

T

M

h

B

a

F

p

2

1

0

F

M
0

M
F

F
B
M

O
M

S

2

0
5

o
C

O

M

S
M
B

rs

M

h

rs
h

36

36

F

D

6

O

M

S
M
B

rs

M

h

rs
h

24

24

F

D

6

O

M

S
M
D

F
B

rs

M

h

rs

12

h

12

h
6

6

O
S

M
6

M
D

F
B

rs

M

rs

h
6

0

M

o
tr
n

0

M

0

l

50

***
100

B

100

150

M

150

G ly c e r o l C o n c e n tr a tio n m M

A ft e r M B F T r e a tm e n t

***

G ly c e r o l C o n c e n t r a t io n  M

A

Figure 11 MBF-induced lipolysis in CFPAC-1 cells.

Figure 11: The Glycerol assay is measuring the glycerol concentration in the medium as
an indication for lipolysis. (A) CFPAC-1 cells treated with MBF at the IC50 dose (6 μM) for
different time points (6, 12, 24, and 36 h) showed a significant increase in the glycerol conc (per
~ 0.2 x 106 cells) only after 36 h treatment, with about doubling the glycerol concentration from
about 45 μM in DMSO treated control cells to about 100 μM with MBF treatment. (B) CFPAC-1
cells treated with 50 μM of MBF produced a significantly higher amount of glycerol compared
with DMSO treated cells (control). Treating the cells with 20 μM of MBF for 12 h did not
change the glycerol conc and pretreating the cells with Thap then combining the MBF did not
produce any change in glycerol conc, as well.
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5.4

Discussion:

As mentioned in the introduction, a high rate of lipogenesis is a crucial process within the
cancer cell. Cancer cells store the produced lipids in the form of LDs for multiple biological
purposes. Because the ER is the major organelle for LDs formation and above results
demonstrated an effect of MBF on the ER, we here investigated whether MBF might affect LDs
in cancer cells.
Initially, the MBF effect on LDs was investigated using oil red O stain in HCC-1806 and
CFPAC-1 cells. Treating HCC-1806 with the IC50 (8 µM) resulted in a significant decrease in the
intensity of the red-stained LDs starting as early as 3 hours after treatment. CFPAC-1 cells
showed similar effect, but a significant reduction in LDs concentration started later than in HCC1806 cells, namely 12 h after MBF treatment with 6 µM. These results suggested that lipid
droplets might indeed undergo lipolysis or lipophagy. The difference in the time course before a
significant decrease in LDs concentration was observed may be due to the different cell types
and might even be due to the fact that CFPAC-1 cells have a difference in ER structure. The
CFPAC pancreatic cancer cells originate from patient that suffered from cystic fibrosis (CF), and
contain a mutant CF gene (Schoumacher et al., 1990), which results in a more condensed ER
around the nucleus and differences in response to Ca2+ signaling (Antigny et al., 2011).
Usually, cancer cells maintain a high concentration of LDs by a continuous process of de
novo lipid synthesis. The decrease of lipid droplets concentration may reflect that the cells are in
a state of starvation (Maan et al., 2018). Therefore, the MBF effect on the LDs was proposed
suggesting that MBF might impact the energy production in cancer cells.
The results from the lipolysis assay showed that MBF-induced lipolysis in CFPAC-1
cells. Treating the cells with MBF 50 µM for 12 h resulted in an 8-fold increase of glycerol
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concentration in the medium; moreover, treating CFPAC-1 cells with MBF at the IC50 dose (6
µM) resulted in a 20% increase in the glycerol concentration after 36 h treatment.
Taken together, MBF caused a reduction in the LDs’ conc in HCC-1806 and CFPAC-1
cells through inducing lipolysis. MBF has been shown to affect the glioma cells plasma
membrane potential by depolarization and by increasing the cytosolic Na+ concentration, causing
the loss of the Na+ concentration gradient necessary for glucose import, and leading to cells
starvation (Niklasson et al., 2017).
Another possible explanation for increased lipolysis may be that MBF treatment caused
in ER stress, which increased the cellular energy demand and resulted in the cell utilizing stored
energy in the form of LDs (Vishnu et al., 2014).

5.5

Conclusion:

MBF caused a decrease in the LDs’ concentration and induced lipolysis in two cancer
cell lines. This effect depletes resources required for the survival of cancer cell, proliferation and
stress resistance. Further investigations are required to determine whether the MBF effect on
LDs is a secondary consequence of ER stress, cell starvation or whether MBF directly stimulates
the production of lipolysis hormones, such as hormone-sensitive lipase.
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6- FINAL DISCUSSION

The effect of MBF on cancer cells was primarily identified on glioma cells, but the
studies were then extended to investigate the anticancer effect of MBF on cancer cells from
epithelium origin (e.g., ovarian and leukemia cancer cells). Interestingly, MBF showed a
significant anticancer effect on both glioma and cancer cells from epithelium origin. Our study
was directed towards identifying the IC50 of MBF for different cell types, verifying the
anticancer effect of MBF, and investigating a potentially common pathway that could be targeted
by anticancer drugs in future studies.
Despite the differences between different cell lines used in this study, such as the CF
gene mutation in CFPAC-1 cells that alters their ER structure-function characteristics
(Schoumacher et al., 1990), MBF inhibited the viability of various cancer cell lines. The
screened IC50 doses of MBF were relatively low in comparison to the FDA approved anticancer
drug doxorubicin.
Because MBF has been described as a TTCC blocker, the first approach was to examine
whether the observed effects of MBF could be explained by its action on TTCC. By using Fura-2
imaging, we demonstrated an increase in [Ca2+]i in response to MBF treatment at IC50 doses of 68 µM, which was an unexpected result for inhibiting a calcium channel. The applied doses were
around 40 times the concentration required for blocking TTCC, whereas MBF administration at a
dose of 0.92 µM (about 5 times IC50 for TTCC) did not show changes in [Ca2+]i. Additional
investigations to examine whether extracellular Ca2+ could be identified as the source of [Ca2+]
increase showed that the increase in [Ca2+]i triggered by MBF was not abolished by eliminating
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the extracellular Ca2+ source, but was blocked by emptying the ER Ca2+ store, which identified
the ER as the source of the MBF-induced [Ca2+]i increase.
The fact that cells rely on mitochondria-associated ER membranes for Ca2+ signaling
raised the possibility that MBF might also have an effect on the mitochondria, secondary to the
Ca2+ release from the ER (Morciano et al., 2018). Results from the TMRE assay indicated that
MBF indeed impacted the MX and resulted in hyperpolarization followed by depolarization of
MX, whereas, emptying the ER Ca2+ store once again blocked the hyperpolarization effect of
MBF. Usually, MX hyperpolarization is associated with ROS overproduction and accumulation
in the mitochondrial inner membrane (Zhang et al., 2006). Suggesting that MBF may elicit a
unique mechanism of inducing overproduction or accumulation of ROS in mitochondria, , which
triggered by MBF-induced Ca2+ release from the ER and blocked by emptying ER Ca2+ stores by
Thap.
On the other hand, MBF-induced Ca2+ release from ER stores and its impact the MX also
suggested that MBF might induce apoptosis in cancer cells. Flow cytometric analysis of
AnnexinV/PI stained cells after MBF treatment showed that MBF was able to induce apoptosis
in CFPAC-1 cells, which was also dependent on MBF-induced ER Ca2+ release.
Recent research demonstrated that cancer cells maintain a tremendous amount of lipids in
LDs, and that the ER is the major site for LD production. However, mitochondria dysfunction
can also regulate cellular lipolysis (Kratky et al., 2014; Maan et al., 2018). Oil red O stain
indicated that MBF decreased the number of LDs in cancer cells, an effect that started taking
place after 3-12 h of MBF treatment at a dose equal to the IC50. Therefore, we sought to clarify
the fate of the disappeared LDs employing a glycerol detection assay. Indeed, glycerol
production by CFPAC-1 cells significantly increased upon MBF treatment at a dose of 6 µM
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after 36 h, and at 50 µM after 12 h. Preliminary results indicated that emptying the ER Ca2+
stores did not halt the lipolysis effect of MBF. Therefore, future studies will have to investigate
in detail how MBF causes increased lipolysis.
Another interesting observation was that the HCC-1806 and CFPAC-1 cells underwent
shrinkage during Fura-2 and TMRE imaging in response to MBF, while cells treated with
DMSO only did not show such phenomenon. One possible explanation might be the high MBF
doses used in those assays, that were at least 6 times the concentration required for inhibiting
voltage-gated Na+ channels and volume-activated Cl- channels and could have restrained the
cells’ ability to maintain their volume.
Our results suggest that the anticancer effect of MBF is likely not related to its well
described effect of blocking TTCC. Instead, the effect of MBF was shown to mainly depend on
releasing Ca2+ stored in the ER. Further investigations are warranted to identify the major
pathways that contribute to mechanism of action caused by MBF. In addition, it will also be
important to evaluate the expression of the major markers of cellular activity, division, and
apoptosis after MBF treatment. Moreover, conducting additional detailed studies to disclose the
effect of MBF on lipid metabolism through monitoring the effect of MBF on the expression of
lipolytic enzymes and perilipins, and ROS production would be of great interest. In parallel,
MBF has a unique effect on the mitochondria and LDs, despite the finding that Thap can also
induce ER stress and Ca2+ release. Together, these findings open multiple doors for future
research opportunities into understanding the effect of ions homeostasis in cancer cells, as well
as lipogesis and LDs dynamics. Further opportunities in investigating the unique effect of MBF
on ER that was shown to be different from the classical ER stressors like Thap, which can help
to identify a common therapeutic target among various cancer cells.
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7- FINAL CONCLUSIONS

In summary, the current research study showed that MBF-induced ER Ca2+ release is
required for the anticancer action of MBF, which challenges the present concept of explaining
the anticancer effect of MBF solely by its known effect of blocking the TTCC. Furthermore, the
MBF-induced Ca2+ release was also essential for inducing a hyperpolarization of the MX and for
cancer cells apoptosis. Understanding the unique effects of MBF will lay the foundation for new
strategies to fight the most resistant and aggressive cancers by targeting essential cell signaling
pathways that were pathologically altered for the benefit of the cancer cell.
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APPENDICES

Appendix A
A-1. Cell Lines and Growing Mediums:
The cancer cell lines used in the study were grown in suitable medium (Corning®) (Table
A-1) and were incubated in 5% CO2 incubator (Nuaire NU-4750, Thermo Scientific 800WJModel 3578) in 37 Co. All the media were provided with 10% Fetal Bovine Serum (HyClone®
Characterized FBS, U.S. Origin, GE Healthcare Life Sciences) and 1% Penicillin-Streptomycin
cocktail (Corning®).
Table A-1: The cancer cell lines used in the study and the suitable medium used for
growing each cell line. All the growing media were supplemented with 10% FBS and 1%
Penicillin-Streptomycin cocktail.
Table 2 The cancer cell lines used in the study and the growing medium.
Cell Line

Growing Media

PC-3 Luc (Prostate cancer cells)

MEM

MDA-MB-231 Luc (TNBC* cells)

DMEM with 4.5% glucose

MDA-MB-468 (TNBC cells)

DMEM

MDA-MB-231 (TNBC cells)

DMEM

HCC-1806 (TNBC cells)

RPMI

DU-145 (Prostate cancer cells)

DMEM

CFPAC-1 (Pancreatic adenocarcinoma cells)

RPMI

Panc-1 (Pancreatic cancer cells)

RPMI

Panc-89 (Pancreatic cancer cells)

DMEM



TNBC: Triple Nigative Breast Cancer cells.
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A.2. The ECS Composition:
The ECS was prepared for providing the cells with non-nutritious, isotonic buffer that
was used for washing the cells after loading the TRME and Fura-2 AM dyes, and for covering
the cells during imaging. The ECS pH and osmolarity are 7.3 and 320 mOsm/L. All the
chemicals used in the formulation were purchased from Sigma-Aldrich®.

Table A-2: The composition of the ECS:
Table 3 The composition formula of ESC
No.

Chemical Compound

Molar conc

Molecular weight
(MW)

The weight (mg) for
preparing 1 L of ECS

1

Sodium chloride (NaCl)

152

58.4

8877

2

Potassium chloride (KCl)

2.8

74.6

209

3

HEPES (4-(2-hydroxyethyl)-1piperazineethanesulfonic acid)

10

238.31

2380

4

Calcium chloride * (CaCl2)

2

111

222

5

Glucose

10

180

1800



For preparing Ca2+ free ECS, the CaCl2 was replaced by the molar concentration of

EGTA (Ethylene glycol-bis [β-aminoethyl ether]-N,N,N',N'-tetraacetic acid, MW 380).
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